BioMed Research International

BioMed Research International / 2014 / Article
Special Issue

Biotechnological Drugs: The Breakthrough in Autoimmune Rheumatic Conditions

View this Special Issue

Research Article | Open Access

Volume 2014 |Article ID 325875 |

Yiping Hu, Ruoxi Liu, Jinchao Li, Ye Yue, Wenxiang Cheng, Peng Zhang, "Attenuation of Collagen-Induced Arthritis in Rat by Nicotinic Alpha7 Receptor Partial Agonist GTS-21", BioMed Research International, vol. 2014, Article ID 325875, 9 pages, 2014.

Attenuation of Collagen-Induced Arthritis in Rat by Nicotinic Alpha7 Receptor Partial Agonist GTS-21

Academic Editor: Lorenzo Cavagna
Received27 Nov 2013
Accepted10 Jan 2014
Published27 Feb 2014


This research was performed to observe the effect of GTS-21 on Collagen Induced Arthritis (CIA). CIA model was used and after the onset of arthritis, the rats were divided into three groups based on their clinical symptoms score. Two groups were intraperitoneally (IP) injected daily with GTS-21 (1 mg/kg, 2.5 mg/kg) for a week, whereas phosphate buffered saline (PBS) was used for the control group. Cytokine titers, radiological, and histological examinations were performed at different time points after treatment with GTS-21. Compared with those of the control, the levels of TNF-α, IL-1, and IL-6 in the serum were significantly reduced after GTS-21 management. In addition, radiological results show that bone degradation was inhibited as well. Moreover, the hematoxylin and eosin (H&E) staining indicated that the histological score was significantly alleviated in the therapeutic group. Tartrate-resistant acid phosphatase (TRAP) stain-positive cells were also detected in the destruction of the articular cartilage, which was significantly reduced compared with the control group. This study provides the first evidence on the effect of GTS-21 as a potential treatment for RA.

1. Introduction

Rheumatoid arthritis (RA) is a systemic autoimmune disorder of unknown etiology that mainly targets diarthrodial joints, synovial membrane first and then cartilage, ligaments, and subchondral bone [1]. The impact of RA is very important in terms of articular pain [2], patients’ functional disability [3], and survival [4, 5], in particular when considering the occurrence of extraarticular manifestations [6, 7]. It has been reported that pro- and anti-inflammatory cytokines derived predominantly from cells of the macrophage lineage have a major role in the initiation and perpetuation of the chronic inflammatory process in the RA synovial membrane [8]. Therefore, several treatment methods for RA aim to block certain cytokines noted to be essential in the development of RA [911]. However, none of these methods can cure this disease at the current stage.

In the last decades, the treatment of RA is deeply changed; now it is well established that early treatment is mandatory in order to improve patients’ prognosis and reach disease remission, which is the main goal that clinicians should now achieve [1214]. The availability of new effective drugs that are able to modulate the inflammatory cascade of RA is another factor that contributes to this “change of perspective” in RA treatment; these drugs are generally known as bio(techno)logical agents and may target TNF [15], CD20+ cells [16], IL-6 [17], and T-cells costimulation [18]. The literature about these drugs is steadily increasing, in terms not only of effectiveness and safety profile description [19, 20], but also of responsiveness prediction [21, 22]. Despite the progresses, the number of unsatisfied needs in RA treatment still remains high, as the large number of biological agents under development suggests [23]. Therefore, new therapeutic methods for RA treatment are of great importance.

The nervous system has been demonstrated to be an important regulator of the immune system, and neuronal anti-inflammatory mechanisms have been selected by evolution to modulate inflammatory responses [24, 25]. These mechanisms can provide a major advantage for novel pharmacological anti-inflammatory strategies that control systemic inflammation [26]. Recent research indicated that acetylcholine, the principal neurotransmitter of the vagus nerve, is a key mediator of this cholinergic anti-inflammatory pathway. The neuronal nicotinic acetylcholine receptors (nAChRs) are named based on their subunit components, in which nicotinic α-7 acetylcholine receptor (α7nAChR) is a subunit of nAChRs [27]. The α7nAChR has been considered important for immune regulation in the absence of nerves; however, little is known about its therapeutic role in chronic joint inflammation. Interestingly, overexpressed α7nAChR in synovial biopsies from patients with RA may be a target in RA therapy [28].

Based on the above mentioned selective pharmacological stimulation of α7nAChR, it may have therapeutic potential for the treatment of inflammatory conditions. Consequently, more specific agonists of this receptor have been identified or developed and used in various studies. To date, one of the most effective α7 selective partial agonists for modulating inflammatory responses is GTS-21, which has been proven effective in attenuating the immune response and improving the outcome in animal models of pancreatitis [29], endotoxemia, sepsis [30], acute lung injury, and ischemia reperfusion injury [3133]. GTS-21 has also been proven effective as an immunomodulatory drug that attenuates pro-inflammatory cytokine levels and improves survival in sepsis models [34], decreases severity in pancreatitis, and attenuates endotoxin-induced tumor necrosis factor (TNF) in lung tissue [31, 35].

However, no research was reported to identify the therapeutic effect of GTS-21 on RA. This study hypothesizes that α7nAChR provides a link between the neurologic system and the inflammatory process in the inflamed joint and that treatment with specific activators (GTS-21) of this receptor would reduce joint inflammation. For this purpose, we used a strain of rats susceptible to CIA, a widely used experimental model of RA, as it shares many histological and immunological features with this disease, such as pannus formation, bone and cartilage destruction, and synovitis as well [36]. In detail, CIA animal model in rat via intraperitoneally (IP) injecting the highly selective α7nAChR agonist GTS-21 was performed and the result was observed and analysed.

2. Materials and Methods

2.1. Animals

A total of 35 male Wistar rats (8 to 10 weeks of age) were purchased from Vital River Laboratory Animal Technology Co. Ltd. (Beijing, China). The animals were housed under special pathogen-free conditions at the animal facility of the Shen Zhen Institute of Advanced Technology, Chinese Academy of Science. The Institutional Animal Care and Use Committee of the Shen Zhen Institute of Advanced Technology, Chinese Academy of Science approved all of the experiments.

2.2. Inducing CIA in Rats

Arthritis was induced in 30 rats by treatment with type II collagen (5 normal rats as control); CIA was induced using a modified method previously described by Trentham et al. [37]. In brief, bovine collagen-II ((CII) Chondrex, 2002, USA, dissolved in 0.05 M acetic acid) was emulsified with an equal volume of incomplete Freund’s adjuvant ((IFA) Chondrex, 7002, USA). This CII-IFA emulsified liquid was administered as a 0.2 mL intradermal injection at the dorsum of each rat’s tail, approximately 2 cm distal from the base. At 10 days after the first immunization, each rat received 0.1 mL of CII-IFA booster via intradermal injection on the tail’s ventral side. For arthritis assessment, all rats were monitored three times a week by the same person blinded to the treatment group, and the incidence of arthritis and clinical score were evaluated.

The severity of arthritis was assessed using an established semiquantitative scoring system of 0–4, where 0 = normal, 1 = swelling in 1 joint, 2 = swelling in >1 joint, 3 = swelling in the entire paw, and 4 = deformity and/or ankylosis [38]. The cumulative score for all four paws of each rat (maximum possible score of 16) was used to represent the overall disease severity and progression.

2.3. In Vivo Administration of GTS-21

To explore the effects of GTS-21 on the CIA rat model, GTS-21 was dissolved in PBS. 15 days after the second immunization, 24 of 30 induced rats showed symptoms of RA and they were divided into three groups, with each group comprising eight rats. The severity of arthritis score in these three groups was the same (each group score: 12) and treatment by drug that day after they were grouped, in which the two groups were receiving a once daily (IP) injection of GTS-21 (1.0 mg/Kg and 2.5 mg/Kg) for a week, whereas the other group was treated by PBS using the same method for a week.

2.4. Enzyme-Linked Immunosorbent Assay (ELISA)

TNF-α, IL-1, and IL-6 levels in the serum were determined after treatment with GTS-21 (7 and 20 days after the treatment), using a commercially available ELISA kits, according to the recommendations of the manufacturer (Neobioscience Technology Co., Ltd.).

2.5. Radiological Analysis

1, 2, and 3 months after being treated with GTS-21, radiographic scoring criteria (28 kv, 12 s, USA Fixitron X-ray) were assessed according to the method reported by Lin et al. [39]: 0 is normal intact bony outlines and normal joint space; 1 is slight abnormality with one or two exterior metatarsal bones showing slight bone erosion; 2 is definite early abnormality with bone erosion in three to five exterior metatarsal bones; 3 is medium destructive abnormality of all exterior metatarsal bones, as well as one to two interior metatarsal bones showing definite bone erosions; 4 is severe destructive abnormality of all the metatarsal bones showing definite bone erosion and at least one of the inner metatarsal joints completely eroded, leaving bony joint outlines partly preserved; and 5 is mutilated abnormality with the absence of decipherable bony outlines. All parameters were scored by at least two observers in a blind test manner.

2.6. Histological Analysis

3 months after the treatment, the rats were sacrificed and hind paws were fixed in 4.0% formalin for 12 hours and then decalcified in 10% EDTA (Sigma) for 20 days at room temperature. The serial paraffin sections (5 μm) of the hind paws were stained with hematoxylin and eosin (HE) for assessment of synovial inflammation and bone erosions, with a leukocyte acid phosphatase staining kit (Sigma) for tartrate-resistant acid phosphatase (TRAP) to detect osteoclasts. All detailed processes were performed according to the recommendations of the manufacturer (Nanjing Jancheng Technology co., Ltd.).

To compare the histological differences among different foot joints, HE sections of different joints were evaluated using the following scale [40]: 0 is normal synovium; 1 is synovial membrane hypertrophy and cell infiltrates; 2 is pannus and cartilage erosions; 3 is major erosions of cartilage and subchondral bone; and 4 is loss of joint integrity and ankylosis. The assessment was performed by two independent investigators who were blinded to the identity of the specimens, and the average of the two scores was obtained. The sample size of each group was 16. TRAP-positive cells found in sections of the knee joints were collected. Specifically, collection of TRAP-positive cells found in six different microscopic fields per section were collected. Osteoclasts were quantified according to the following scores: 0 = normal (no osteoclasts), 1 = presence of a few osteoclasts (lining fewer than 5% of most affected bone surfaces), 2 = some osteoclasts (lining 5–25% of most affected bone surfaces), 3 = many osteoclasts (lining 30–50% of most affected bone surfaces), and 4 = abundant osteoclasts (lining >50% of most affected bone surfaces) [41].

2.7. Statistical Analysis

To evaluate the effects of different treatments, we determined the change in clinical arthritis scores in each mouse from the start of the treatment until the end of the experiment. A nonparametric test (Kruskal-Wallis test) was used to analyze the score data, including radiological and histological scores. The statistical significance level was set at a value of 0.05 and 0.01. SPSS 17.0 was used for all experiments.

3. Results

3.1. CIA Model

The macroscopic observation of joint swelling is shown in Figure 1. Joint swelling in the CIA model rats (Figure 1(b)) was significantly higher than that of the normal rats (Figure 1(a)). The severity of arthritis was assessed using an established semiquantitative scoring system, and the results are shown in Figure 1(c).

3.2. Cytokine Level in Peripheral Blood Serum

After treatment with GTS-21 and PBS (7 and 20 days), the serum concentrations of TNF-α, IL-1, and IL-6 were tested using ELISA. The results showed that the cytokine levels in the treatment groups were significantly lower than those in the control group, as shown in Figures 2(a), 2(b), and 2(c).

3.3. Radiological Observation

Radiographs of the knee and foot joints were evaluated to investigate the effects of GTS-21 on bone degradation. The X-ray results were shown in Figures 3(a), 3(b), and 3(c). In the third month after treatment, in the PBS treated group normal joints in the knees and toes could barely be seen, but GTS-21 treated group significantly improved on joint destruction, whereas the semiquantitative scoring of joint destruction was shown in Figure 3(d). All the dates indicated that joint destruction was significantly reduced in the group treated with GTS-21.

3.4. Histological Analysis

Synovial inflammation and joint erosions were assessed by HE staining of ankle joint specimens, as shown in Figures 4(a), 4(b), and 4(c). Histologic scoring revealed a significant reduction of inflammatory cell infiltration in rats treated with GTS-21 compared with the control group (Figure 4(d)). In the knee joint, many TRAP stain-positive cells adhered to the eroded surface of the cartilage, which directly contributed to the erosion of such cartilage (Figures 5(a), 5(b), and 5(c)). Meanwhile, subchondral side erosion severity and pannus abundant were observed in the PBS treatment group. Moreover, it destroyed the joint from outside the cartilage. The score of osteoclasts in the knee joint of the treatment groups was significantly lower than that of the control group (Figure 5(d)). By contrast, no difference was observed between two different drug concentrations in the treatment groups with regard to histological and radiological scoring.

4. Discussion

Studies have indicated that α7nAChR is important for immune regulation [42]. Specific stimulation of α7nAChR on monocytes leads to efficient suppression of pro-inflammatory cytokine production. This receptor is essential for the efficient cytokine regulation in neuroimmune mechanisms known as the cholinergic anti-inflammatory pathway [43, 44]. RA is a chronic, inflammatory autoimmune disease of unknown cause and may be related to several signaling pathways. M. Westman et al. [28] reported the strong expression of α7nAChR in synovium of RA patients. These results indicated the importance of α7nAChR and cholinergic mechanisms in arthritis pathogenesis and implicated specific cholinergic modulation as a potential anti-inflammatory therapeutic strategy in joint inflammation.

GTS-21 is a derivative of the natural product anabaseine which is an effective portion of α7nAChR agonists. Moreover, GTS-21 is a characteristic α7nAChR-agonist that has been used in clinical trials and has been proven to be less toxic than nicotine [45, 46]. It has been reported that GTS-21 has been used in clinical trials to target neuronal α7nAChR in the brain of patients with Alzheimer’s disease [47], since the cholinergic anti-inflammatory pathway is activated by stimulating the α7nAChR [33]. Meanwhile, the high expression of α7nAChR in the synovium of RA patients is a potential target of RA treatment and offers the possibility of GTS-21 as RA therapeutic drug.

In the present study, based on the newly discovered cholinergic anti-inflammatory pathway, we proposed a new method for the treatment of CIA using GTS-21. In our study, 7 and 20 days after treatment with GTS-21, those cytokines were significantly reduced relative to the control group. Based on observation of the inflammatory cell in the HE stained sections, the inflammatory environment was significantly improved in the treatment group. Furthermore, the treatment group had arthritis-related inflammatory cytokines that were much lower than those of the control group, which displayed significant inhibitory effects.

Bone and cartilage destruction are among the main symptoms of RA. We observed the destruction of knee joint at different times by radiology and measurement scores. As the disease developed, inhibitory effects were observed in the treatment group, opposite that of the control group, in which the joint was destroyed more seriously. This phenomenon was also observed in foot joints (results not shown). Osteoclast related erosion is one of the main factors of bone destruction in arthritis. In our observation of the osteoclast score, we found that the score of osteoclasts in the joints of the treatment group was lower than that of the control group. Many inflammatory cytokines, such as TNF-α, have already been proven to have important roles in osteoclast [48, 49]. Hence, the reduction of the secretion of cytokines in the treatment group could reduce the number of osteoclast, thereby reducing bone damage. Accordingly, we observed consistent results in our study, in which joint destruction was reduced in the treatments groups compared with the control group.

In summary, the results of the present study showed the anti-inflammatory effects of GTS-21 as a partial agonist of α7nAChR. GTS-21 may have a new function on the treatment of RA. However, our results showed that drug concentration has no obvious correlation with the effect of treatment. This observation may be attributed to the fact that the difference between the two concentrations of this study was not large enough. Using these questions, more in-depth study is needed in our next work. As the therapeutic value of GTS-21 is selective, this agonist may be a suitable candidate for development as a novel approach to RA treatment.

Conflict of Interests

The authors declare that there is no conflict of interests in this paper.


This research was supported by the National Natural Science Foundation of China (no. 81000786 and no. 81271952).


  1. D. L. Scott, F. Wolfe, and T. W. J. Huizinga, “Rheumatoid arthritis,” The Lancet, vol. 376, no. 9746, pp. 1094–1108, 2010. View at: Publisher Site | Google Scholar
  2. R. Caporali, L. Cavagna, and C. Montecucco, “Pain in arthritis,” European Journal of Pain Supplements, vol. 3, no. 2, pp. 123–127, 2009. View at: Publisher Site | Google Scholar
  3. B. Fautrel and C. Gaujoux-Viala, “Medical and economic aspects of rheumatoid arthritis,” Bulletin de l'Academie Nationale de Medecine, vol. 196, no. 7, pp. 1295–1305, 2010. View at: Google Scholar
  4. A. Ogdie, K. Haynes, A. B. Troxel et al., “Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study,” Annals of the Rheumatic Diseases, vol. 73, no. 1, pp. 149–153, 2014. View at: Publisher Site | Google Scholar
  5. C. Meune, E. Touzé, L. Trinquart, and Y. Allanore, “High risk of clinical cardiovascular events in rheumatoid arthritis: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis,” Archives of Cardiovascular Diseases, vol. 103, no. 4, pp. 253–261, 2010. View at: Publisher Site | Google Scholar
  6. L. Cavagna, S. Monti, V. Grosso et al., “The multifaceted aspects of interstitial lung disease in rheumatoid arthritis,” BioMed Research International, vol. 2013, Article ID 759760, 13 pages, 2013. View at: Publisher Site | Google Scholar
  7. L. Cavagna, N. Boffini, G. Cagnotto, F. Inverardi, V. Grosso, and R. Caporali, “Atherosclerosis and rheumatoid arthritis: more than a simple association,” Mediators of Inflammation, vol. 2013, Article ID 147354, 8 pages, 2012. View at: Publisher Site | Google Scholar
  8. P. Zhang, D. Han, T. Tang, X. Zhang, and K. Dai, “Inhibition of the development of collagen-induced arthritis in Wistar rats through vagus nerve suspension: a 3-month observation,” Inflammation Research, vol. 57, no. 7, pp. 322–328, 2008. View at: Publisher Site | Google Scholar
  9. R. Kokkola, J. Li, E. Sundberg et al., “Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity,” Arthritis and Rheumatism, vol. 48, no. 7, pp. 2052–2058, 2003. View at: Publisher Site | Google Scholar
  10. B. Bresnihan, J. M. Alvaro-Gracia, M. Cobby et al., “Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist,” Arthritis and Rheumatism, vol. 41, no. 12, pp. 2196–2204, 1998. View at: Google Scholar
  11. K. Åkerlund, H. Erlandsson Harris, K. J. Tracey et al., “Anti-inflammatory effects of a new tumour necrosis factor-alpha (TNF-α) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats,” Clinical and Experimental Immunology, vol. 115, no. 1, pp. 32–41, 1999. View at: Publisher Site | Google Scholar
  12. G. Sakellariou, C. A. Scire, S. M. Verstappen, C. Montecucco, and R. Caporali, “In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis,” Annals of the Rheumatic Diseases, vol. 72, no. 2, pp. 245–249, 2013. View at: Publisher Site | Google Scholar
  13. E. Gremese, F. Salaffi, S. L. Bosello et al., “Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study,” Annals of the Rheumatic Diseases, vol. 72, no. 6, pp. 858–862, 2013. View at: Publisher Site | Google Scholar
  14. J. S. Smolen, R. Landewe, F. C. Breedveld et al., “EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update,” Annals of the Rheumatic Diseases, 2013. View at: Publisher Site | Google Scholar
  15. S. Blüml, C. Scheinecker, J. S. Smolen, and K. Redlich, “Targeting TNF receptors in rheumatoid arthritis,” International Immunology, vol. 24, no. 5, pp. 275–281, 2012. View at: Publisher Site | Google Scholar
  16. A. Bagust, A. Boland, J. Hockenhull et al., “Rituximab for the treatment of rheumatoid arthritis,” Health Technology Assessment, vol. 13, supplement 2, pp. 23–29, 2009. View at: Google Scholar
  17. M. Y. Md Yusof and P. Emery, “Targeting interleukin-6 in rheumatoid arthritis,” Drugs, vol. 73, no. 4, pp. 341–356, 2013. View at: Publisher Site | Google Scholar
  18. P. Emery, “The therapeutic potential of costimulatory blockade with CTLA4lg in rheumatoid arthritis,” Expert Opinion on Investigational Drugs, vol. 12, no. 4, pp. 673–681, 2003. View at: Publisher Site | Google Scholar
  19. P. Sarzi-Puttini, M. Antivalle, A. Marchesoni et al., “Efficacy and safety of anti-TNF agents in the Lombardy Rheumatoid Arthritis Network (LORHEN),” Reumatismo, vol. 60, no. 4, pp. 290–295, 2008. View at: Google Scholar
  20. F. Atzeni, P. Sarzi-Puttini, A. Mutti, S. Bugatti, L. Cavagna, and R. Caporali, “Long-term safety of abatacept in patients with rheumatoid arthritis,” Autoimmunity Reviews, vol. 12, no. 12, pp. 1115–1117, 2013. View at: Google Scholar
  21. F. Atzeni, S. Bongiovanni, A. Marchesoni et al., “Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores,” Joint Bone Spine, 2013. View at: Publisher Site | Google Scholar
  22. L. Quartuccio, M. Fabris, E. Pontarini et al., “The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study,” Annals of the Rheumatic Diseases, 2013. View at: Publisher Site | Google Scholar
  23. G. R. Burmester, E. Feist, and T. Dorner, “Emerging cell and cytokine targets in rheumatoid arthritis,” Nature Reviews, 2013. View at: Publisher Site | Google Scholar
  24. L. Ulloa, “The vagus nerve and the nicotinic anti-inflammatory pathway,” Nature Reviews Drug Discovery, vol. 4, no. 8, pp. 673–684, 2005. View at: Publisher Site | Google Scholar
  25. M. A. Van Maanen, M. C. Lebre, T. Van Der Poll et al., “Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice,” Arthritis and Rheumatism, vol. 60, no. 1, pp. 114–122, 2009. View at: Publisher Site | Google Scholar
  26. S. L. Oke and K. J. Tracey, “The inflammatory reflex and the role of complementary and alternative medical therapies,” Annals of the New York Academy of Sciences, vol. 1172, pp. 172–180, 2009. View at: Publisher Site | Google Scholar
  27. W. R. Kem, V. M. Mahnir, L. Prokai et al., “Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration,” Molecular Pharmacology, vol. 65, no. 1, pp. 56–67, 2004. View at: Publisher Site | Google Scholar
  28. M. Westman, M. Engström, A. I. Catrina, and J. Lampa, “Cell specific synovial expression of nicotinic alpha 7 acetylcholine receptor in rheumatoid arthritis and psoriatic arthritis,” Scandinavian Journal of Immunology, vol. 70, no. 2, pp. 136–140, 2009. View at: Publisher Site | Google Scholar
  29. D. J. van Westerloo, I. A. Giebelen, S. Florquin et al., “The vagus nerve and nicotinic receptors modulate experimental pancreatitis severity in mice,” Gastroenterology, vol. 130, no. 6, pp. 1822–1830, 2006. View at: Publisher Site | Google Scholar
  30. V. A. Pavlov, M. Ochani, L.-H. Yang et al., “Selective α7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis,” Critical Care Medicine, vol. 35, no. 4, pp. 1139–1144, 2007. View at: Publisher Site | Google Scholar
  31. I. A. J. Giebelen, D. J. Van Westerloo, G. J. LaRosa, A. F. De Vos, and T. Van Der Poll, “Local stimulation of α7 cholinergic receptors inhibits LPS-induced TNF-α release in the mouse lung,” Shock, vol. 28, no. 6, pp. 700–703, 2007. View at: Publisher Site | Google Scholar
  32. X. Su, W. L. Jae, Z. A. Matthay et al., “Activation of the α7 nAChR reduces acid-induced acute lung injury in mice and rats,” American Journal of Respiratory Cell and Molecular Biology, vol. 37, no. 2, pp. 186–192, 2007. View at: Publisher Site | Google Scholar
  33. M. Kox, J. F. van Velzen, J. C. Pompe, C. W. Hoedemaekers, J. G. van der Hoeven, and P. Pickkers, “GTS-21 inhibits pro-inflammatory cytokine release independent of the Toll-like receptor stimulated via a transcriptional mechanism involving JAK2 activation,” Biochemical Pharmacology, vol. 78, no. 7, pp. 863–872, 2009. View at: Publisher Site | Google Scholar
  34. I. A. J. Giebelen, D. J. Van Westerloo, G. J. LaRosa, A. F. De Vos, and T. Van Der Poll, “Stimulation of α7 cholinergic receptors inhibits lipopolysaccharide-induced neutrophil recruitment by a tumor necrosis factor α-independent mechanism,” Shock, vol. 27, no. 4, pp. 443–447, 2007. View at: Publisher Site | Google Scholar
  35. M. Rosas-Ballina, R. S. Goldstein, M. Gallowitsch-Puerta et al., “The selective α7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE,” Molecular Medicine, vol. 15, no. 7-8, pp. 195–202, 2009. View at: Publisher Site | Google Scholar
  36. R. Holmdahl, M. E. Andersson, T. J. Goldschmidt et al., “Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity,” APMIS, vol. 97, no. 7, pp. 575–584, 1989. View at: Google Scholar
  37. D. E. Trentham, A. S. Townes, and A. H. Kang, “Autoimmunity to type II collagen: an experimental model of arthritis,” Journal of Experimental Medicine, vol. 146, no. 3, pp. 857–868, 1977. View at: Google Scholar
  38. J. van Holten, K. Reedquist, P. Sattonet-Roche et al., “Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis,” Arthritis Research & Therapy, vol. 6, no. 3, pp. R239–R249, 2004. View at: Google Scholar
  39. H.-S. Lin, C.-Y. Hu, H.-Y. Chan et al., “Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents,” British Journal of Pharmacology, vol. 150, no. 7, pp. 862–872, 2007. View at: Publisher Site | Google Scholar
  40. T. Tomita, E. Takeuchi, N. Tomita et al., “Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy,” Arthritis and Rheumatism, vol. 42, no. 12, pp. 2532–2542, 1999. View at: Google Scholar
  41. G. Schett, M. Stolina, D. Dwyer et al., “Tumor necrosis factor α and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis,” Arthritis and Rheumatism, vol. 60, no. 9, pp. 2644–2654, 2009. View at: Publisher Site | Google Scholar
  42. K. Kawashima, T. Fujii, Y. Moriwaki, H. Misawa, and K. Horiguchi, “Reconciling neuronally and nonneuronally derived acetylcholine in the regulation of immune function,” Annals of the New York Academy of Sciences, vol. 1261, pp. 7–17. View at: Google Scholar
  43. M. Pohanka, “Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology,” International Journal of Molecular Sciences, vol. 13, no. 2, pp. 2219–2238, 2012. View at: Publisher Site | Google Scholar
  44. B. Cai, F. Chen, Y. Ji et al., “Alpha7 cholinergic-agonist prevents systemic inflammation and improves survival during resuscitation,” Journal of Cellular and Molecular Medicine, vol. 13, no. 9, pp. 3774–3785, 2009. View at: Publisher Site | Google Scholar
  45. M. Nanri, N. Kasahara, J. Yamamoto, H. Miyake, and H. Watanabe, “A comparative study on the effects of nicotine and GTS-21, a new nicotinic agonist, on the locomotor activity and brain monoamine level,” Japanese Journal of Pharmacology, vol. 78, no. 3, pp. 385–389, 1998. View at: Publisher Site | Google Scholar
  46. E. M. Meyer, A. Kuryatov, V. Gerzanich, J. Lindstrom, and R. L. Papke, “Analysis of 3-(4-hydroxy, 2-methoxybenzylidene)anabaseine selectivity and activity at human and rat alpha-7 nicotinic receptors,” Journal of Pharmacology and Experimental Therapeutics, vol. 287, no. 3, pp. 918–925, 1998. View at: Google Scholar
  47. C. Conejero-Goldberg, P. Davies, and L. Ulloa, “Alpha7 nicotinic acetylcholine receptor: a link between inflammation and neurodegeneration,” Neuroscience and Biobehavioral Reviews, vol. 32, no. 4, pp. 693–706, 2008. View at: Publisher Site | Google Scholar
  48. S. Ochi, M. Shinohara, K. Sato et al., “Pathological role of osteoclast costimulation in arthritis-induced bone loss,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 27, pp. 11394–11399, 2007. View at: Publisher Site | Google Scholar
  49. L. Geboes, B. De Klerck, M. Van Balen et al., “Freund's complete adjuvant induces arthritis in mice lacking a functional interferon-γ receptor by triggering tumor necrosis factor α-driven osteoclastogenesis,” Arthritis and Rheumatism, vol. 56, no. 8, pp. 2595–2607, 2007. View at: Publisher Site | Google Scholar

Copyright © 2014 Yiping Hu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.